Plain English
Bennett et al. (2016, Cochrane Database of Systematic Reviews) is the cornerstone of the evidence base for HBOT in cancer survivorship — specifically for late radiation tissue injury (LRTI), one of HBOT's 14 FDA-approved indications. The Cochrane Database is the highest-tier evidence framework in clinical medicine; this is the formal pub4 review.
What the review measured. Healing outcomes for tissues damaged by prior radiation therapy that emerge months to years after the original treatment — including osteoradionecrosis (bone death), radiation proctitis (rectal injury), radiation cystitis (bladder injury), late radiation lymphedema, soft-tissue radionecrosis, and surgical-flap salvage in irradiated fields. Outcomes pooled across the 14 component RCTs include mucosal coverage, complete clinical resolution, pain relief, and reduced morbidity.
Who was studied. 753 participants pooled across the 14 component trials. Most were head-and-neck cancer survivors with osteoradionecrosis, pelvic-radiation survivors with cystitis or proctitis, or post-surgical patients in previously-irradiated tissue. Trials varied in geography, run-in period, and concurrent standard care.
Protocol parameters. The review summarizes a range across the 14 trials. The typical clinical and FDA-approved protocol is 2.0–2.4 ATA, 100% oxygen, 90-minute sessions, 5 days per week, for 30–40 sessions. Component trials varied within this range.
Results (verbatim from abstract). HBOT was associated with improved outcome for radiation tissues of the head, neck, anus, and rectum. HBOT also appeared to reduce the chance of osteoradionecrosis following tooth extraction in previously-irradiated patients. There was no evidence of any important clinical effect on neurological tissues — an important null finding the authors flagged. The authors recommended further research on optimum participant selection and timing.
Limitations. Heterogeneity across the 14 component trials in indication, protocol detail, and outcome measurement. The review's conclusions are strongest for head/neck and anorectal tissues, weakest for neurological. The pub5 update by Lin et al. 2023 (PMID 37585677) extends and supersedes this review with newer data — the Saturate site indexes both as separate citations to allow readers to navigate the evidence chronology.
What it means in practice. Late radiation tissue injury is one of HBOT's strongest insurance-covered indications in the US. Most major insurers, including Medicare, cover hospital-based HBOT for the FDA-approved subset of LRTI presentations. The 2.0–2.4 ATA pressure required is delivered in hospital hard-shell chambers; soft-shell home chambers cannot replicate the protocol. The Saturate Cancer Survivorship condition page treats this as a clinical-only indication.
How it relates to other indexed trials. Bennett 2016 sits alongside Lin 2023 (the pub5 update) and Kranke 2015 (Cochrane chronic wounds) as the three Cochrane reviews that anchor the wound-healing thread on the Saturate site. The mechanism (angiogenesis, stem-cell mobilization, restored perfusion to damaged tissue) is the same biology driving Hadanny ED 2018 (penile angiogenesis), Zhang 2022 (diabetic foot ulcer healing), and Hachmo 2021 (dermal regeneration).
Source: PubMed PMID 27123955.